DRRX - Durect Corp Stock Price, Fair Value and News

$1.91

Market Closed as of 11 Sep 2025, 04:00 pm ET

DRRX Stock Valuation Analysis

Valuation

Max Portfolio %

DRRX Price Action

DRRX RSI Chart

DRRX Stock Valuation Analysis

Valuation

Max Portfolio %

DRRX Valuation

DRRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DRRX Fundamentals

DRRX Revenue

DRRX Earnings

DRRX Profitability

DRRX Investor Care

Revenue & Growth

How Durect Corp generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2025	-	-	-	-
2024	2.5M	2.3M	2.2M	2.0M
2023	15.9M	9.3M	5.9M	2.6M
2022	13.7M	13.5M	23.3M	19.3M
2021	30.7M	8.5M	8.9M	14.0M
2020	26.3M	27.6M	28.9M	30.1M
2019	19.2M	19.8M	21.5M	25.1M
2018	48.1M	47.2M	34.5M	18.6M
2017	15.0M	16.1M	33.1M	49.2M
2016	18.0M	16.7M	15.7M	14.0M
2015	17.9M	17.7M	18.2M	19.1M
2014	17.5M	18.1M	19.4M	19.4M
2013	16.0M	15.2M	14.3M	15.3M
2012	66.1M	63.0M	58.7M	53.1M
2011	32.5M	33.0M	33.0M	33.5M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Durect Corp

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

CEO	Dr. James E. Brown D.V.M.
WEBSITE	durect.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	72